The settlement of this federal securities fraud class action lawsuit is on behalf of investors who purchased or otherwise acquired Celgene Corporation (“Celgene”) (NASDAQ: CELG) common stock between April 27, 2017 and April 27, 2018, inclusive (the “Class Period”).
Celgene agreed to pay $239,900,000 to resolve this class action lawsuit alleging the company and certain of its officers and/or directors violated federal securities laws by making false or misleading statements.
What’s the status of the Settlement?
On December 19, 2025, the Court granted Kessler Topaz Meltzer & Check’s Motion for Preliminary Approval of the Class Action Settlement which was filed on behalf of the Lead Plaintiffs. There is a Final Settlement Hearing scheduled for May 4, 2026. The settlement website is active and open for claims.
Who can file a claim?
The settlement class includes all persons or entities who:
- Purchased or otherwise acquired Celgene common stock between April 27, 2017 and April 27, 2018, inclusive.
How much is the Settlement Payment?
Pro rata payment: The total settlement fund is $239,000,000. The amount each class member receives will depend on several factors, including:
- The number of valid claims submitted
- The number of shares purchased and sold
- The dates of purchase and sale
- The price paid for the shares and the price received upon sale
How do I file a claim?
The deadline to file a claim is April 13, 2026. To submit a claim and/or to find additional information regarding the terms of the settlement and claim filing process, go to www.CelgeneSecuritiesLitigation.com, or contact the claims administrator, JND Legal Administration, at 1-855-648-0893.
For more information on the case and the Settlement, please visit our website at https://www.ktmc.com/featured-case/celgene-corp-inc.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com.